Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients

Paroxetine is a phenylpiperidine compound which is a selective serotonin reuptake inhibitor (SSRI). Ninety-one hospitalised patients with a major depression (DSM-III) aged 65 and over from six Austrian and one German center were entered into the study, which compared the efficacy and tolerability of...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacologia 1995-06, Vol.119 (3), p.277-281
Main Authors: GERETSEGGER, C, STUPPAECK, C. H, MAIR, M, PLATZ, T, FARTACEK, R, HEIM, M
Format: Article
Language:English
Subjects:
Aged
Aging - drug effects
Amitriptyline - pharmacology
Biological and medical sciences
Depression - drug therapy
Double-Blind Method
Female
Humans
Male
Medical sciences
Neuropharmacology
Paroxetine - adverse effects
Paroxetine - pharmacology
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Paroxetine is a phenylpiperidine compound which is a selective serotonin reuptake inhibitor (SSRI). Ninety-one hospitalised patients with a major depression (DSM-III) aged 65 and over from six Austrian and one German center were entered into the study, which compared the efficacy and tolerability of paroxetine versus amitriptyline. After 6 weeks both groups showed similarly good therapeutic results. In the paroxetine group, 64.3% of the patients had a 50% or more reduction of the HAMD total score compared to 58.1% in the amitriptyline group. Side effects were distributed similarly in both groups. Patients in the paroxetine group showed a higher incidence of anxiety and agitation; anticholinergic side effects were registered more often in the amitriptyline group.
ISSN:0033-3158
1432-2072
DOI:10.1007/BF02246291